Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations
From MaRDI portal
(Redirected from Publication:5122852)
Recommendations
- Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: opportunities and limitations
- Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts
- How practical are adaptive designs likely to be for confirmatory trials?
- Plan to be Flexible: A Commentary on Adaptive Designs
- Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: methods, simulation model and their implementation in R
Cited in
(31)- A comparison of methods for constructing confidence intervals after phase II/III clinical trials
- SEAMLESS PHASE II/III CLINICAL TRIALS WITH COVARIATE ADAPTIVE RANDOMIZATION
- Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts
- How practical are adaptive designs likely to be for confirmatory trials?
- Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: opportunities and limitations
- A comparison of methods for adaptive treatment selection
- Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: methods, simulation model and their implementation in R
- Blinded sample size recalculation in adaptive enrichment designs
- Blinded sample size recalculation in multiple composite population designs with normal data and baseline adjustments
- Two-stage randomized clinical trials with a right-censored endpoint: comparison of frequentist and Bayesian adaptive designs
- Adding experimental treatment arms to multi-arm multi-stage platform trials in progress
- A conditional error function approach for adaptive enrichment designs with continuous endpoints
- Point estimation for adaptive trial designs. II: Practical considerations and guidance
- Seamless phase 2/3 oncology trial design with flexible sample size determination
- Adaptive enrichment trials: what are the benefits?
- Enhancing the flexibility and power of adaptive seamless phase 2/3 design with copula modeling between short-term and long-term endpoints
- Two-stage drop-the-losers design for the selection of effective treatments and estimating their average worth
- Efficient testing of the biomarker positive and negative subgroups in a biomarker-stratified trial
- Optimizing the data combination rule for seamless phase II/III clinical trials
- A varying-stage adaptive phase II/III clinical trial design
- A Bayesian adaptive dose selection procedure with an overdispersed count endpoint
- Group sequential designs with prospectively planned rules for subpopulation enrichment
- Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls
- DOD-SSR: an adaptive seamless phase II/III design with dose optimization decision and sample size re-estimation
- Group sequential enrichment design incorporating subgroup selection
- Accurate p-values for adaptive designs with binary endpoints
- Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials
- Optimal seamless phase 2/3 oncology trial designs based on probability of success (PoS)
- Making all pairwise comparisons in multi-arm clinical trials without control treatment
- A comparison of methods for treatment selection in seamless phase II/III design
- A multi-stage drop-the-loser design with superiority boundaries
This page was built for publication: Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5122852)
